TYMS-Polymorphismen und Empfindlichkeit gegenüber oder Toxizität von Methotrexat bei rheumatoider Arthritis

Sang Cheol Bae; Young Ho Lee

doi:10.1007/s00393-018-0419-4

TYMS-Polymorphismen und Empfindlichkeit gegenüber oder Toxizität von Methotrexat bei rheumatoider Arthritis

Translated title of the contribution: TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis

Sang Cheol Bae, Young Ho Lee

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. Results: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682–1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281–1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. Conclusions: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.

Translated title of the contribution	TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis
Original language	German
Pages (from-to)	824-832
Number of pages	9
Journal	Zeitschrift fur Rheumatologie
Volume	77
Issue number	9
DOIs	https://doi.org/10.1007/s00393-018-0419-4
Publication status	Published - 2018 Nov 1

Bibliographical note

Funding Information:
Acknowledgements. This study was supported in part by a grant of the Korea Healthcare technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI15C2958).

Publisher Copyright:
© 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Keywords

Methotrexate
Rheumatoid arthritis
TYMS polymorphism

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s00393-018-0419-4

Cite this

@article{de5fbe77eaa24404820c31938277e6b8,

title = "TYMS-Polymorphismen und Empfindlichkeit gegen{\"u}ber oder Toxizit{\"a}t von Methotrexat bei rheumatoider Arthritis",

abstract = "Objective: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. Results: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682–1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281–1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. Conclusions: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.",

keywords = "Methotrexate, Rheumatoid arthritis, TYMS polymorphism",

author = "Bae, {Sang Cheol} and Lee, {Young Ho}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s00393-018-0419-4",

language = "German",

volume = "77",

pages = "824--832",

journal = "Zeitschrift fur Rheumatologie",

issn = "0340-1855",

publisher = "D. Steinkopff-Verlag",

number = "9",

}

TY - JOUR

T1 - TYMS-Polymorphismen und Empfindlichkeit gegenüber oder Toxizität von Methotrexat bei rheumatoider Arthritis

AU - Bae, Sang Cheol

AU - Lee, Young Ho

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Objective: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. Results: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682–1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281–1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. Conclusions: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.

AB - Objective: The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods: We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients. Results: A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682–1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281–1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models. Conclusions: This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.

KW - Methotrexate

KW - Rheumatoid arthritis

KW - TYMS polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85041100304&partnerID=8YFLogxK

U2 - 10.1007/s00393-018-0419-4

DO - 10.1007/s00393-018-0419-4

M3 - Article

C2 - 29380036

AN - SCOPUS:85041100304

SN - 0340-1855

VL - 77

SP - 824

EP - 832

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

IS - 9

ER -

TYMS-Polymorphismen und Empfindlichkeit gegenüber oder Toxizität von Methotrexat bei rheumatoider Arthritis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this